Influence of Stroke on the Composition of Intestinal Microbiota
NCT ID: NCT02008604
Last Updated: 2018-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
24 participants
OBSERVATIONAL
2014-06-30
2018-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults
NCT05113043
Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke
NCT07247838
Gut Microbiota in Acute Stroke Patients
NCT03934021
Cognition and Gut Microbiome Associated Study of Shanghai People With Acute Ischemic Stroke
NCT03812445
Gut Microbiota and Serum Markers for Cognitive Impairment and Poor Prognosis After Ischemic Stroke
NCT04688138
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stroke patients
No interventions assigned to this group
TIA patients
patients with a transient ischemic attack (control group)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ischemic cerebral infarction within the last 40 hours, anterior circulation infarct (ACA, MCA) and/or posterior circulation infarct (PCA, BA) of any severity
* patient consent or consent by a legal representative
* NIHSS \> or =9 (stroke patients)
* NIHSS \< 1 (for TIA patients)
Exclusion Criteria
* preexisting dysphagia
* signs of infection upon admission (clinical/paraclinical)
* existing antibiotic therapy upon admission or within the last 2 weeks before admission
* mechanical ventilation upon admission
* participation in an interventional therapy study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dr. Ulrich Dirnagl, Experimental Neurology, Charité Berlin, Germany
UNKNOWN
Dr. Christian Meisel, Medical Immunology, Charité Berlin, Germany
UNKNOWN
PD Dr. Andreas Nitsche, Robert-Koch-Institut, Berlin, Germany
UNKNOWN
NeuroCure Clinical Research Center, Charite, Berlin
OTHER
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andreas Meisel
Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Meisel, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charite Universitätsmedizin Berlin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUTSTROKE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.